Abstract |
The novel folate analogue AG2034, which was designed as an inhibitor of GARFT ( glycinamide ribonucleotide formyltransferase), was evaluated in this phase I study under the auspices of The Cancer Research Campaign, UK. AG2034 blocks de novo purine synthesis through inhibition of GARFT. A total of 28 patients with histologically proven intractable cancers were enrolled. AG2034 was administered as a short intravenous infusion once every 3 weeks. 8 dose levels ranging from 1-11 mg/m(2)were evaluated with patients receiving up to 6 cycles. Dose-limiting toxicities in the form of mucositis, diarrhoea and vomiting were observed at doses of 6 mg/m(2)and above. Significant levels of thrombocytopenia, neutropenia and anaemia were also recorded. Other sporadic toxicities included fatigue and myalgia. The MTD with this schedule of AG2034 was 5 mg/m(2). Most side effects occurred more frequently with cumulative dosing. In keeping with this, pharmacokinetic analysis revealed evidence of drug accumulation. The AG2034 AUC(0-24)increased by a median of 184% (range 20-389%) from cycle 1 to 3 in all 10 patients examined. No objective antitumour responses were observed in the study.
|
Authors | D Bissett, H L McLeod, B Sheedy, M Collier, Y Pithavala, L Paradiso, M Pitsiladis, J Cassidy |
Journal | British journal of cancer
(Br J Cancer)
Vol. 84
Issue 3
Pg. 308-12
(Feb 02 2001)
ISSN: 0007-0920 [Print] England |
PMID | 11161393
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Glutamates
- Pyrimidines
- AG 2034
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, pharmacokinetics)
- Area Under Curve
- Diarrhea
(chemically induced)
- Dose-Response Relationship, Drug
- Female
- Glutamates
(administration & dosage, adverse effects, pharmacokinetics)
- Humans
- Male
- Middle Aged
- Mouth Mucosa
(drug effects, pathology)
- Nausea
(chemically induced)
- Neoplasms
(drug therapy, metabolism)
- Neutropenia
(chemically induced)
- Pyrimidines
(administration & dosage, adverse effects, pharmacokinetics)
- Stomatitis
(chemically induced)
- Thrombocytopenia
(chemically induced)
- Treatment Outcome
|